Current Issues in the Surgical Management of Breast Cancer: A Review of Abstracts from the 2002 San Antonio Breast Cancer Symposium, the 2003 Society of Surgical Oncology Annual Meeting, and the 2003 American Society of Clinical Oncology Meeting

Breast Journal

Volumn 10, Issue 1 SUPPL., 2004, Pages

  Newman, Lisa A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; MASTECTOMY; MEDICAL SOCIETY; SAFETY; SENTINEL LYMPH NODE BIOPSY; TUMOR LOCALIZATION;

EID: 0942301287     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2004.101s8.x     Document Type: Conference Paper

References (26)

1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus radiation for the management of invasive breast cancer. N Engl J Med 2002;347:1233-41.
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347: 1227-32.
3. Poggi MM, Danforth DN, Sciuto LC, et al. Cancer events after 18 years of follow-up in the treatment of early-stage breast cancer with mastectomy versus breast conservation therapy [abstract 28]. San Antonio Breast Cancer Symposium, 2002.
4. Leong C, Boyages J, Bilous M, et al. The effect of margins on ipsilateral breast tumour recurrence after breast conservation therapy for node-negative breast cancer [abstract 448]. San Antonio Breast Cancer Symposium, 2002.
5. Smitt M, Nowels K, Jeffrey S, et al. Predictors of re-excision findings and recurrence with breast-conserving therapy [abstract 449]. San Antonio Breast Cancer Symposium, 2002.
6. Locker G, Sainsbury R, Cuzick J, et al. The ATAC Trialists' Group. Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy. San Antonio Breast Cancer Symposium, 2002.
7. Cutuli B, Lemanski C, LeBlanc M, et al. Local recurrences after DCIS therapy: diagnosis, treatment, and outcome [abstract 31]. San Antonio Breast Cancer Symposium, 2002.
8. Truong PT. [abstract]. San Antonio Breast Cancer Symposium, 2002.
9. Kim T, Agboola O, Lyman GH. Lymphatic mapping and sentinel node sampling in breast cancer: a meta-analysis [abstract 139]. Proceedings of the American Society of Clinical Oncology Meeting, Orlando, FL, 2003.
10. Fisher B, Jeong JH, Anderson S, et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-75.
11. Kattan MW, Tan LK, Borgen PI, et al. A multivariate nomogram to predict likelihood of non-sentinel node metastases in breast cancer patients with positive sentinel nodes [abstract 84]. Society of Surgical Oncology Annual Meeting, Los Angeles, CA, 2003.
12. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
13. Kuerer HM, Sahin A, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases prior to surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-78.
14. Newman LA, Singletary SE, Buzdar AU, Kuerer HM, Buchholz TA, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast conservation therapy feasibility. Ann Surg Oncol 2002;9:228-34.
15. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304-10.
16. Mamounas EP, Brown A, Smith R, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: updated results from NSABP B-27 [abstract 140]. Proceedings of the American Society of Clinical Oncology Meeting, Chicago, IL, 2003.
17. Zirngibl C, Steinfeld-Birg D, Vogt H, et al. Sentinel lymph node biopsy before neoadjuvant chemotherapy: conservation of breast and axilla [abstract 516]. San Antonio Breast Cancer Symposium, 2002.
18. Sabel MS, Schott AF, Pierce IJ, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy [abstract 28]. Society of Surgical Oncology Annual Meeting, Los Angeles, CA, 2003.
19. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-32.
20. Willey SC, Rezaei K, Hegde P, et al. Ductal lavage: Initial 18 month experience at a single institution [abstract 112]. San Antonio Breast Cancer Symposium, 2002.
21. Francescatti D, Kluskens L. Ductal lavage using aseptic technique in a series of 100 high-risk women [abstract 110]. San Antonio Breast Cancer Symposium, 2002.
22. Masood S, Khalbuss W, Siddiqi AM. Exfoliative breast cytology: an experience with ductal lavage [abstract 113]. San Antonio Breast Cancer Symposium, 2002.
23. Khan SA, Rodriguez N, Baird C, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy [abstract 25]. San Antonio Breast Cancer Symposium, 2002.
24. Dooley WC, Clark A, Parker J. The frequency of ductal atypia in high-risk breast tissue [abstract 29]. Society of Surgical Oncology Annual Meeting, Los Angeles, CA, 2003.
25. Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat 1993;28:157-66.
26. Carpenter CL, Loves M. Ductal cells, hyperplasia, and breast cancer risk: results from a long-term follow-up study of lavage patients [abstract 109] San Antonio Breast Cancer Symposium, 2002.